Showing results (61-70 of 73) with videos related to
Sort By:
Pageof 8
Comparative Immunology, Microbiology and Infectious Diseases|September 12, 2012
Comparative study of class 1 integron, ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, tetracycline (ACSSuT) and fluoroquinolone resistance in various Salmonella serovars from humans and animalsYuan-Man Hsu, Chiu-Ying Tang, Hsuan Lin, et al.Journal for Immunotherapy of Cancer|April 8, 2021
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockadeRomain Banchereau, Avantika S Chitre, Alexis Scherl, et al.Plos One|September 15, 2010
Molecular biomarker analyses using circulating tumor cellsElizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, et al.Cell Reports. Medicine|January 4, 2023
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancerAdrian M Jubb, Kathy D Miller, Hope S Rugo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer ImmunotherapyF Stephen Hodi, Marcus Ballinger, Benjamin Lyons, et al.Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.Cancer Immunology Research|April 3, 2016
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research InstituteIra Mellman, Vanessa M Hubbard-Lucey, Matthew J Tontonoz, et al.Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.Pageof 8